BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, United States
- Yale University
New Haven, Connecticut, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Northwestern University
Chicago, Illinois, United States
- Haysmed
Hays, Kansas, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- Lawrence Memorial Hospital
Lawrence, Kansas, United States
- the University of Kansas Cancer Center - Olathe
Olathe, Kansas, United States
- University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
- Mercy Hospital Pittsburg
Pittsburg, Kansas, United States
- Salina Regional Health Center
Salina, Kansas, United States
- University of Kansas Health System Saint Francis Campus
Topeka, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- University Health Truman Medical Center
Kansas City, Missouri, United States
- University of Kansas Cancer Center - North
Kansas City, Missouri, United States
- University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
- University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, United States
- Siteman Cancer Center at Christian Hospital
St Louis, Missouri, United States
- Siteman Cancer Center-South County
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
- Wake Forest University at Clemmons
Clemmons, North Carolina, United States
- Wake Forest Baptist Health - Wilkes Medical Center
Wilkesboro, North Carolina, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Feb 2021
- Primary completion
- 5 Jun 2023
- Completion
- 30 Jan 2027
- Last update posted
- 1 Jun 2026
- Registered enrollment
- 60
- Registry id
- NCT04284787
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.